未治療肺結核に対する強化化学療法に関する研究--SM・INH・RFP併用術式とSM・INH・EB併用術式との比較

概要

論文の詳細を見る
The results at 6 months of a controlled trial of two regimens are presented. Adults with newly-diagnosed sputum-positive pulmonary tuberculosis were treated in hospital for 6 months. They were submitted from 4 chest clinics and were allocated at random to: - A. SM 1g daily for 3 months, followed by SM 1 g biweekly+INH 0.6g daily +RFP 0.45 gdaily B. SM 1g daily for 3 months, followed by SM 1g biweekly+INH 0.6 g dail +EB 15 mg/kg daily A total of 50 patients was admitted to the study. Of these, 44 (26 in regimen A, 18 in regimen B) patients were included in a main comparison, even if they had had changes or in terruptions of chemotherapy due to drug toxicity or other reasons. In the remaining 6 patients, there were 3 early discharges and 3 bacteriologically negative cases. At 6 months, none of the patients in regimen A had an unfavorable bacteriological response. On the contrary, 5 patients in regimen B showed culturable tubercle bacilli in their sputum off and on after 12 weeks' chemotherapy, even if in some of the cases the original regimen was changed to the presumably more potent regimens. As for the rapidity of the sputum conversion to negative, regimen A showed 73% negative conversion at 4 weeks, though regimen B showed only 44%. Although the courses of X-ray findings had no significant differences between these two regimens, the rapidity of the negative conversion of the sputum on -culture as well as overall favorable bacteriological response of regimen A suggest its superiority to regimen B. The adverse reaction of daily 1 g SM was not trivial in its frequency. In case of daily use, the dose less than 1 g will be more suitable.
一般社団法人日本結核病学会の論文

未治療肺結核に対する強化化学療法に関する研究--SM・INH・RFP併用術式とSM・INH・EB併用術式との比較

スポンサーリンク

概要

著者

関連論文

スポンサーリンク